

10/587356

Atty. Dkt. No. 059718-0108

IAP5 Rec'd PCT/PTO 26 JUL 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Marie Nathalie KOLOPP-SARDA et al.
Title: METHOD OF DIAGNOSING INFECTIOUS DISEASE BY
MEASURING THE LEVEL OF SOLUBLE TREM-1 IN A
SAMPLE
Appl. No.: U.S. National Stage of PCT/GB2005/000273
Filing Date: Concurrently Herewith
Examiner: Unassigned
Art Unit: Unassigned
Confirmation Number: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

Copies of references A3-A5 are being submitted to comply with the provisions of 37 CFR §1.97 and §1.98. Copies of references A6-A11 will be submitted at a later date.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

10/587356

Atty. Dkt. No. 059718-0108

IAP5 Rec'd PCT/PTO 26 JUL 2006

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.


Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date

July 26, 2006

By



FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: July 25, 2006 (use as many sheets as necessary)				Complete if Known 10/587356													
Sheet		1	of	1	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">U.S. National Stage of PCT/GB2005/000273</td> </tr> <tr> <td>Filing Date</td> <td>Concurrently Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Marie Nathalie KOLOPP-SARDA</td> </tr> <tr> <td>Group Art Unit</td> <td>Unassigned</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>059718-0108</td> </tr> </table>	Application Number	U.S. National Stage of PCT/GB2005/000273	Filing Date	Concurrently Herewith	First Named Inventor	Marie Nathalie KOLOPP-SARDA	Group Art Unit	Unassigned	Examiner Name	Unassigned	Attorney Docket Number	059718-0108
Application Number	U.S. National Stage of PCT/GB2005/000273																
Filing Date	Concurrently Herewith																
First Named Inventor	Marie Nathalie KOLOPP-SARDA																
Group Art Unit	Unassigned																
Examiner Name	Unassigned																
Attorney Docket Number	059718-0108																

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	2003/165875	A1	Marco COLONNA et al.	09-04-2003	
	A2	6,420,526	B1	Steven M. RUBEN et al.	07-16-2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A3	WO	2002/058721	A	Baylor College of Medicine	08-01-2002		
	A4	WO	2004/035732	A	Five Prime Therapeutics, Inc.	04-29-2004		
	A5	WO	2004/081233	A	BioXell S.P.A.	09-23-2004		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A6	BOUCHON et al., "Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes," <i>Journal of Immunology</i> , vol. 164, 2000, pages 4991-4995.			
	A7	NATHAN et al., "TREM-1: a new regulator of innate immunity in sepsis syndrome," <i>Nature Medicine</i> , vol. 7, No. 5, 2001, pages 530-532.			
	A8	BOUCHON et al., "TREM-1 amplifies inflammation and is a crucial mediator of septic shock," <i>Nature</i> , vol. 410, no. 6832, April 26, 2001, pages 1103-1107			
	A9	COLONNA et al., "TREM-1 (triggering receptor expressed on myeloid cells): a new player in acute inflammatory responses," <i>Journal of Infectious Diseases</i> , vol. 187, no. SUPPL 2, June 15, 2003, pages S397-S401.			
	A10	NOCHI et al., "Modulation of hepatic granulomatous responses by transgene expression of DAP12 or TREM-1-Ig molecules," <i>American Journal of Pathology</i> , vol. 162, no. 4, April 2003, pages 1191-1201.			
	A11	GINGRAS et al., "TREM-1 MDL-1, and DAP12 expression is associated with a mature stage of myeloid development," <i>Molecular Immunology</i> , vol. 38, no. 11, March 2002, pages 817-824.			

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.